Background IL-16 has been described as a natural soluble CD4-ligand with immunosuppressive effects in vitro. However, little is known about the effect of IL-16 on immune responses in vivo. Objective In the present study, we examined the effect of IL-16 administration in a murine model of allergic asthma. Next, we determined whether these effects were mediated by modulation of CD4
Introduction

CD4
T cells, following mitogen, antigen or anti-CD3 stimulation, release IL-16. In addition to T lymphocytes, eosinophils, mast cells, dendritic cells, ®broblasts, B cells and epithelial cells can release bioactive IL-16 [1] . Previously, we demonstrated that IL-16 immunoreactivity is present in epithelial cells of ovalbumin-sensitized mice but not in naõ Ève animals [2] . Upon antigen-challenge, increased IL-16 expression was observed in epithelial cells and in both in¯ammatory cell in®ltrates and bronchoalveolar lavage (BAL)¯uid [2] . Similarly, IL-16 expression in epithelial cells and presence of bioactive IL-16 in BAL uid after antigen challenge has been observed in asthmatics [1] . It has clearly been demonstrated that IL-16 uses the CD4 molecule as its receptor and exerts diverse functional activities via CD4 signalling in lymphocytes and eosinophils [1] . IL-16 is a well-known chemoattractant for CD4 cells in vitro [1, 3] . In contrast to this immunostimulatory effect, IL-16 has also been shown to have immunosuppressive effects both in vitro and in vivo, e.g. inhibition of anti-CD3-induced proliferation, antigen-induced T cell activation in human T cells derived from atopics, and inhibition of rheumatoid synovitis [4±8] .
Previously, we demonstrated that administration of antibodies to IL-16 reduces development of airway hyperresponsiveness, without affecting airway eosinophilia in a mouse model of allergic asthma [9] . These data would suggest that endogenous IL-16, in asthmatic in¯ammation, has a proin¯ammatory effect. To reconcile the differences between the apparent pro-in¯ammatory effect, observed using neutralizing antibodies, and the direct immunosuppressive effect of IL-16, observed in vitro, we investigated the ability of exogenously added IL-16 to alter the in¯ammatory response in the murine model of allergic asthma. In these studies antigen-sensitized mice were treated with IL-16 [intraperitoneally (i.p)] during the antigen-challenge period and the effect on airway responsiveness to methacholine as well as development of in¯amma-tion was assessed. We observed a signi®cant decrease in airway responsiveness after treatment with IL-16. Histological sections and cell differentials from lavage¯uid con®rmed the lack of eosinophilia and epithelial cell hyperplasia in IL-16-treated animals. The mechanism for the IL-16-induced immunosuppression in this model appears to be related to the ability of IL-16 to preferentially inhibit Th2 T cell cytokine production.
Antigenic re-stimulation of isolated T cells from lung draining lymph nodes in IL-16-treated mice produced signi®cantly less Th2 cytokines compared with untreated mice. The in¯uence of IL-16 on T cell differentiation was also investigated as a potential mechanism for inhibition of Th2 cytokine production. Stimulation of naõ Ève DO11.10 transgenic T cells with IL-16 resulted in reduced Th2 cytokine production with no inhibition of IFNg. While the presence of IL-16 in asthmatic lungs has been known for many years, this is the ®rst in vivo report of the immunosuppressive role of IL-16 in the development of airway in¯ammation.
Materials and methods
The animal care committee of the Utrecht University approved all experiments.
Sensitization and challenge
Speci®ed pathogen-free male BALB/C mice (6±8 weeks) were obtained from the breeding colony of the Central Animal Laboratory (Utrecht, the Netherlands). Active sensitization ± 10 mg ovalbumin (grade V) in 0.5 mL saline [2] ± was performed on alternate days (seven times). Four weeks thereafter, mice were exposed (5 min) to eight ovalbumin (2 mg/mL in saline) or saline aerosols ( jet nebulizer: Pari IS-2, Pari-Werk GmbH, Starnberg, Germany), on consecutive days (one/day). Before each aerosol the mice were injected i.p. with 1 mg rmIL-16 (in 0.25 mL saline) or vehicle. For the T cell differentiation experiments, spleens were used from DO11.10 TCR transgenic mice (donated by L. Adorini, Department of In¯ammation/Autoimmune Diseases, Hoffmann-La Roche Inc., Nutley, NJ, USA) [10] .
Airway responsiveness in vivo
Airway responsiveness was measured using whole-body barometric plethysmography (Buxco Corp., Sharon, CT, USA, with a pressure transducer, M45, Validyne Engineering Corp. Northridge, CA, USA; see [11] for more details and validation of this method). Although this technique has many advantages, the contributions of a nasal component in the measurements need to be taken into account, e.g. no discrepancy can be made between nasal congestion and lung responses. As indirect parameter for detection of airway responsiveness to methacholine PENH was used. Baseline PENH values were established by averaging for 3 min (average of 10 valid breaths per PENH value). Mice were subjected to a saline aerosol, followed by increasing concentrations of nebulized methacholine (1±50 mg/mL) for 3 min, followed by a measuring period of 3 min after each aerosol. Aerosol was generated using a jetnebulizer (Pari IS-2, Par-Werk GmbH).
Bronchoalveolar lavage
Bronchoalveolar lavages were performed as published previously [2] in the same animals that were used for airway hyperresponsiveness measurements.
Ovalbumin-speci®c IgE enzyme-linked immunosorbent assay
Ovalbumin-speci®c IgE in serum was measured as published previously [2] .
Cytokine production by thoracic lymph node cells in vitro T cells were isolated using immunomagnetic negative selection [see 13 for details]. In short, lymphocytes were isolated (Lympholyte M gradient, Cedarlane, Hornby, Ontario, Canada) from splenocytes (DO11.10 TCR transgenic mice) and incubated (1 Â 10 7 cells/mL) with antibodies to MHC-II (MKD6), CD8 (YTS69), Thy1 (YTS154), B220 (RA3±6B2) and CD16/32 (2.4G2) in previously established dilutions (FACS-scan). Negative immunomagnetic selection was performed using magnetic beads coupled to mIgG2a, rIgG2b and mIgM antibodies (Perseptive Biosystems, Boston, MA, USA). The resultant CD4 population was 80±90% pure (FACS-scan, data not shown).
Splenocytes from BALB/c mice were used (1 Â 10 6 /mL) as antigen presenting cells (APCs) and cultured (5 Â 10 5 /mL) with CD4 DO11.10 T cells in the presence of ovalbumin 323À339 (OVA 323-339 ) peptide (0.3 mg/mL, 1, 5 mL/well). Supernatant fractions were harvested after 4 days, non-viable cells were removed (Lympholyte M gradient, Cedarlane Õ ) and remaining cells (5 Â 10 5 cells/mL) were re-stimulated (1 Â 10 6 /mL APCs) with OVA 323-339 (0.3 mg/mL). Supernatants were again harvested after 2 days for cytokine analysis. During the ®rst antigen stimulation, cells were cultured with or without rmIL-16 (1 mg/mL). Experiments were performed at least in triplicate.
Lung histology
Lungs from IL-16-treated or control mice were excised and processed for histology as previously described [2] . Brie¯y, lung tissue was in¯ated using 4% paraformaldehyde. Following dehydration the tissue was embedded in paraf®n and sectioned at 4-mm thickness. The sections were stained with haematoxylin and eosin to characterize lung in¯ammation and identify tissueassociated eosinophils.
Chemicals
Ovalbumin (chicken egg albumin crude grade V) was purchased from Sigma Chemical Company (St Louis, MO, USA). Methacholine (acetyl-b-methylcholine) was purchased from Janssen Chimica (Beerse, Belgium). rmIL-16 used in the cultures was obtained from Pharmingen and rmIL-16 used in vivo was produced as previously published [3] . OVA 323-339 was obtained from the Faculty of Veterinary Sciences, Utrecht University, Utrecht, the Netherlands. Antibodies used in this study were MKD6 (anti-I-A d , mIgG2a), YTS169 (anti-CD8, rIgG2b), YTS154 (anti-Thy1, rIgG2b), RA3±6B2 (anti-B220, rIgG2b) and 2.4G2 (anti-muFc g RII; CD16/32, rIgG2b). All antibodies were puri®ed by standard protein A or G column af®nity using supernatants of hybridoma cultures maintained at Utrecht University, the Netherlands. Hematoxylin and eosin stain were obtained from Fisher Diagnostics (Suwanee, GA, USA).
Data analysis
Unless stated otherwise data are expressed as mean + standard error of the mean (SEM) and evaluated using an analysis of variance followed by a post-hoc comparison between groups.
Data on proliferation or cytokine levels were analysed using a paired Student's t-test. For cell types with low numbers in control animals (i.e. neutrophils and eosinophils) a Poisson distribution was assumed. A difference was considered to be signi®cant when P < 0.05. Statistical analyses were carried out using SPSS/PC , version 4.0.1 (SPSS Inc., Chicago, IL, USA).
Results
Effect of treatment with IL-16 on airway hyperresponsiveness in vivo
In vehicle-treated ovalbumin-challenged mice the increase in airway responsiveness to aerosolized methacholine was enhanced signi®cantly when compared to saline-challenged animals ( Fig. 1a ) as demonstrated by a signi®cant increase in PENH values, an indirect parameter for airway functioning [see 11 for details and validation]. At the highest concentration of methacholine (50 mg/mL), the PENH in saline-treated animals was 4.5 + 0.9, whereas in ovalbumin-challenged animals PENH was 9.4 + 1.7 (P < 0.05). Administration of rmIL-16 during the aerosol challenge period completely prevented (P < 0.05) ovalbumin-induced airway hyper-responsiveness (Fig. 1b) . At the highest concentration of methacholine the PENH in rmIL-16-treated ovalbumin-challenged animals was 5.0 + 0.5, whereas PENH in saline-challenged mice was 6.2 + 1.7. These data indicate that the systemic administration of IL-16 results in the complete inhibition of increased airway hyper-responsiveness in this model.
Effect of treatment with IL-16 on number of eosinophils in BAL¯uid
To see whether the effect of IL-16 on antigen-induced airway hyper-responsiveness was accompanied by alterations in airway in¯ammation, the lungs were lavaged and presence of in¯ammatory cells was determined. Ovalbumin challenge of vehicle-treated animals resulted in a signi®cant (P < 0.05) increase in the number of eosinophils in BAL¯uid compared to vehicle-treated saline-challenged mice (162 + 85 Â 10 3 vs. 0.4 + 0.3 Â 10 3 cells, respectively, Fig. 2 ). Treatment with rmIL-16 during the aerosol challenge period resulted in a signi®cant (P < 0.05) decrease of ovalbumin-induced eosinophil in®ltration compared to vehicle-treated ovalbumin-challenged animals (13.9 + 7.5 Â 10 3 cells, Fig. 2 ). No signi®cant differences in in®ltration of mononuclear cells or neutrophils were observed between different groups of animals. Furthermore, no differences were observed in total numbers of cells that were present in BAL¯uid (Table 1) . following assessment of airway physiology lungs from IL-16-treated or control mice were excised and processed for histology. As depicted in Fig. 3 , lungs from ovalbumin-sensitized and challenged mice demonstrated a marked increase in immune cell recruitment that appeared to be both perivascular as well as peribronchial. Epithelial cell hyperplasia was also noted. In contrast, lungs from mice treated with IL-16 demonstrated very little increase in immune cell recruitment as compared with saline-challenged (control) mice. In addition, the thickness of the epithelium appeared to be normal (Fig. 3) . Taken together these data indicate that the presence of IL-16 results in signi®cantly less airway hyper-responsiveness and in¯ammation in this model of allergic asthma.
Effect of treatment with IL-16 on lung in¯ammation
Effect of treatment with IL-16 on ovalbumin-speci®c IgE levels in serum
A decreased in¯ammatory response in this model could arise as a result of insuf®cient production of ovalbumin-speci®c IgE antibodies. To determine if this was a contributing factor, ovalbumin-speci®c IgE antibody was assessed. Ovalbumin challenge of vehicle-treated animals resulted in an almost ®vefold increase (P < 0.05) in serum levels of ovalbumin-speci®c IgE when compared to saline-challenged mice (745 + 209 vs. 174 + 55 units/mL, respectively, n 5). Ovalbumin challenge of IL-16-treated animals also resulted in a signi®cant (P < 0.05) increase of serum IgE levels when compared to saline-challenged animals (768 + 50 vs. 271 + 84 units/mL, respectively, n 5). No signi®cant differences were observed between serum IgE levels of vehicle or IL-16-treated animals challenged with either saline or ovalbumin.
Effect of treatment with IL-16 in vivo on antigen-speci®c cytokine production in vitro 
Effect of pre-incubation with IL-16 on TLN cells in vitro
The immunosuppressive effect of IL-16 seen with in vivo treatment could occur by a number of different mechanisms. To determine whether this was a direct effect on Th2 cells, TLN cells were isolated following ovalbumin sensitization and airway challenge, and then treated with or without IL-16 prior to antigenic stimulation. Antigen-speci®c re-stimulation in vitro of TLN cells derived from ovalbumin-sensitized and challenged animals resulted in an increase in IL-4 production when compared to cells cultured with medium alone (2.25 + 1.55 vs. 0.01 + 0.01 ng/mL). In a concentration-dependent fashion, IL-16 decreased IL-4 production up to 56% at 1 mg/mL. IL-5 production was also enhanced (P < 0.05) by ovalbumin stimulation in vitro when compared to cells cultured with medium alone (1.45 + 0.46 vs. 0 ng/mL). Pre-incubation of TLN cells in vitro with rmIL-16 also signi®cantly decreased (P < 0.05) ovalbumin-induced IL-5 production up to 77% at 1 mg/mL. TLN cells stimulated with ovalbumin in vitro displayed a signi®cant (P < 0.05) increase in proliferation when compared to cells cultured without ovalbumin (11 447 + 2509 vs. 1618 + 472[ 3 H]-incorporation in cpm). Pre-incubation of TLN cells with rmIL-16 (1 mg/mL) signi®cantly (P < 0.05) decreased in vitro proliferation up to 55% after stimulation with ovalbumin. IFNg levels in supernatants derived from ovalbumin-stimulated TLN cells were below detection levels (0.3 ng/ mL, data not shown). Culturing TLN cells with IL-16 in the absence of ovalbumin did not induce cytokine production or proliferation (data not shown). Stimulation of T cells by IL-16 therefore results in a decrease in antigen-induced Th2 cytokine production. This effect appears to be direct as similar results were obtained using only TLN cells in vitro.
Effect of IL-16 on generation of DO11.10 effector lymphocytes
A decrease in Th2 cytokine production can occur as a result of inhibiting Th2 T cell responsiveness to antigenic stimulation and/or by affecting T cell differentiation. Because in vivo treatment with IL-16 decreases Th2-type cytokine production by TLN cells stimulated with antigen in vitro we investigated whether the observed in vivo anti-in¯ammatory effect of IL-16 could be caused by alteration of T cell differentiation. To determine whether IL-16 has an in¯uence on the differentiation of CD4
T cells into Th1-or Th2-type T cells, we used CD4
T cells isolated from DO11.10 mice. CD4 T cells were isolated and cultured for 4 days in the presence of APCs and OVA 323-339 with or without rmIL-16. Thereafter, non-viable cells were removed and remaining cells were re-stimulated with antigen and freshly isolated APCs and cultured for an additional 2-day period in the absence of IL-16. Cytokine levels in supernatants were determined both at the end of the ®rst stimulation period and after the second stimulation period with OVA 323-339 .
Cells maintained in medium and stimulated with OVA 323-339 produce IL-5, low levels of IL-4 and IL-10, and a high amount of IFN-g (Table 2 ). Cytokine levels in supernatants derived from cells cultured in medium with rmIL-16 after the ®rst stimulation period did not differ from levels measured in cultures without IL-16 (Table 2) . During the second culture period, OVA 323-339 induced production of IL-4, IL-5, IL-10 and IFN-g (Table 2 ), which is indicative of a Th0-type cytokine pro®le. Upon re-stimulation with antigen, cells generated in presence of IL-16 produce less IL-4 (P < 0.05) and IL-5 (P < 0.05), whereas IL-10 and IFN-g levels were not altered in these supernatant fractions ( Table 2) . As IL-16 was not present during the second stimulation period, the decrease in Th2 cytokines would suggest the presence of less Th2 cells in cultures previously stimulated with IL-16. These data suggest that the presence of IL-16 not only inhibits Th2 cell activation and cytokine production, but also may in¯uence the differentiation of Th1 and Th2 cells.
Discussion
In this study we demonstrate for the ®rst time, that administration of IL-16 during the antigen-challenge period has potent immunosuppressive effects in a murine model of allergic asthma. IL-16 administration inhibited antigen-induced eosinophil in®ltration and airway hyper-responsiveness but did not affect up-regulation of antigen-speci®c IgE levels in serum. The bene®cial effects of IL-16 appear to be caused by inhibition of proliferation and cytokine production of antigenspeci®c type-2 lymphocytes. The Th2-type CD4 T lymphocyte is of main importance for development of airway hyper-responsiveness and eosinophilia [14±18] . In murine models it has been shown that IL-4 and IL-13 play essential roles in antigen-induced airway hyperresponsiveness and eosinophilia. However, a crucial role for IL-5 in the development of airway hyper-responsiveness is still under debate [9, 19] . Since IL-16 uses CD4 as its receptor [1] , the CD4 T lymphocyte is a likely candidate for the direct effects of IL-16 treatment. However, we can not exclude that IL-16 exerts its in vivo immunosuppressive actions through an alternative receptor, as the possibility exists that CD4 is not required for IL-16-induced signalling in cells of the monocyte lineage [20] .
At present, little is known about the effect of IL-16 on type-2 cytokine production by T lymphocytes in vivo. Here we demonstrate that treatment with IL-16 in vivo inhibits antigenstimulated production of IL-4 and IL-5 in vitro by lymphocytes isolated from lung draining lymph nodes. Moreover, preincubation of TLN cells derived from sensitized and antigenchallenged animals with IL-16 in vitro also inhibits antigen-speci®c Th2-type cytokine production and proliferation. This is consistent with the reports that addition of rhIL-16 to antigen-stimulated human peripheral blood mononuclear cell (PBMC) cultures signi®cantly reduces the amount of IL-5 [8] . However, in the PBMC cultures of human atopics IFN-g levels were signi®cantly increased, suggesting a further shift towards a Th1-type cytokine pro®le [8] . This observation could not be con®rmed in our studies as IFN-g could not be detected in either TLN cultures from IL-16-treated animals, or in supernatants from in vitro pre-incubated TLN cultures upon antigen re-stimulation.
In agreement with our data, IL-16 has been shown to suppress the mixed lymphocyte reaction as well as antigen or anti-CD3-induced proliferation of human CD4
T cells in vitro when added prior to stimulation [4, 5] . Moreover, the anti-in¯ammatory activity of IL-16 is supported by the fact that in vivo administration of IL-16 results in inhibition of CD4 T cell mediated responses in a murine model of human rheumatoid synovitis [7] , and prevents skin graft rejection in an in vitro model [6] . Similar to the down-regulatory actions of IL-16, other CD4 ligands such as antibodies to CD4 and HIV-1 gp120 have also been shown to be immunosuppressive in various models [21±24] . While the mechanism for the immunosuppressive effect of any of these CD4 ligands has not been elucidated, it is likely attributable to the ability to disrupt CD4 autoaggregation and CD4±T cell receptor complex formation, both requirements for optimal T cell activation.
In addition to inhibition of Th2 T cell activation, IL-16 may also in¯uence the development of T cell differentiation. It is well known that the CD4 molecule plays a role in differentiation of T cells into Th2-type effector cells [13] , besides having an accessory function in TCR-induced signalling. We found that the presence of IL-16 during priming cultures of naive DO11.10 CD4
T cells induces an effector phenotype that displays a decreased production of IL-4 and IL-5 but normal levels IL-10 and IFN-g upon re-stimulation. As already mentioned, both IL-4 and IL-5 are necessary for development of allergyassociated parameters, whereas both IL-10 and IFN-g have been demonstrated to be potent inhibitors of Th2-type T cellmediated responses in vivo [25, 26] . Such a shift in the balance between pro-and anti-allergic cytokines may contribute to the observed in vivo effects of exogenous IL-16. However, it should be stressed that we used an arti®cial in vitro T cell differentiation system using DO11.10 T cells, which are highly speci®c for OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] . Furthermore, as already discussed, in vivo treatment with IL-16 does not induce IFN-g production by T cells isolated from lung draining lymph nodes and therefore further research is required to elucidate the importance of this observation for our in vivo ®ndings.
It is interesting to note that IL-16-treated DO11.10 cells did not display decreased cytokine production after the ®rst antigen stimulation. This is consistent with the concept that only memory cells are susceptible to CD4-induced unresponsiveness, whereas naive T cells are not [27] . Moreover, freshly isolated DO11.10 CD4
T cells demonstrated a naive phenotype, as was indicated by high expression of CD45 RB and CD62L/l-selectin (data not shown), whereas TLN cells, isolated from antigensensitized and repeatedly challenged animals are likely to have a memory/effector phenotype and are therefore more susceptible to CD4-mediated unresponsiveness. Indeed, it has been shown that CD4 high CD62L low lymphocytes are responsible for the passive transfer of allergic in¯ammation [17] . Finally, it is well known that CD4 expression increases when T cells are exposed to antigen, which could render these T cells more susceptible for CD4 ligands.
Previously, we have observed that administration of anti-IL-16 antibody during the challenge period partially decreased airway hyper-responsiveness, whereas eosinophilic in®ltration was not affected [2] . Those data would initially appear to be contradictory with the data presented in this study. However, the two protocols are addressing two different concepts of IL-16 biology. The earlier study investigated the potential role of endogenous IL-16 by using neutralizing antibodies. In that model the major cell source of IL-16 is the airway epithelium. Production of low levels of IL-16 selectively in the lung, by virtue of establishing a tissue-speci®c concentration gradient, could attract CD4 cells to the lungs, contributing to the inammatory response. Neutralization of the IL-16 would result in fewer recruited cells. The magnitude of the inhibition would re¯ect the contribution of IL-16 bioactivity to airway hyperreactivity and in¯ammation. In the current model, systemic administration of IL-16 results in high circulating levels of IL-16. Under these conditions, it is likely that the effects of IL-16 are similar to what is seen in vitro, inhibition of T cell activation and cytokine production. As potentially all CD4 T cells would be exposed to IL-16, the magnitude of the inhibitory effect would be greater. This concept would support our data where IL-16 treatment resulted in almost complete inhibition of increased airway hyper-reactivity and in¯ammation. It is unclear at present whether endogenous levels of IL-16 reach levels required for induction of immunosuppression. Understanding the in vivo role of IL-16 in allergic in¯ammation will be greatly enhanced with data generated from an IL-16 knockout mouse.
Finally, in our study, IgE production was not inhibited by administration of IL-16, whereas IL-4 production by TLN cells was decreased. This seems to contradict the generally accepted essential role of IL-4 in IgE-synthesis. However, upon repeated encounter with antigen, IgE production by B cells is less dependent on cognate B±T cell contact and on the presence of IL-4 [28] . It could thus be hypothesized that lower levels of IL-4 in our model would not signi®cantly alter IgE production by memory B cells.
In conclusion, we are the ®rst to demonstrate that IL-16, a natural CD4 ligand, has immunosuppressive effects in vivo on both antigen-induced in¯ammatory responses as well as airway hyper-responsiveness. Although the precise mechanism remains to be elucidated, we demonstrate that in vivo immunosuppressive effects of IL-16 are associated with inhibition of Th2-type cytokine production. As IL-16 has been detected in association with a number of in¯ammatory conditions, it is tempting to speculate that this process for regulating Th2 T cell activation is not restricted to the lung but may represent a more widely utilized mechanism in the development of allergic in¯ammation.
